BCLI实时信号 | 通过Getagraph.com最大化利润

购买 121113 min ago

@ $0.370

发出时间: 9 Feb 2024 @ 22:30

回报率: 10.54%

上一信号: Feb 9 - 03:29

上一信号: 出售

回报率: -6.68 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 01:00):

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases...

Stats
今日成交量	228 860
平均成交量	991 593
市值	27.96M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.0700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.020
ATR14	$0.00700 (1.71%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Lebovits Chaim	Buy	15 000	Common Stock
2024-04-17	Dagher Ibrahim B.	Buy	0	Common Stock
2024-04-17	Dagher Ibrahim B.	Sell	0	Common Stock
2024-04-17	Dagher Ibrahim B.	Buy	0	Common Stock
2024-04-18	Lebovits Chaim	Buy	115 072	Common Stock

INSIDER POWER
100.00
Last 89 transactions
Buy: 3 045 109 \| Sell: 254 714

音量相关性

長: -0.41 (neutral)

短: 0.43 (neutral)

Signal:(54.227) Neutral

Brainstorm Cell 相关性

10 最正相关
PWFL	0.914
NATR	0.905
APOP	0.893
RAIL	0.892
QADB	0.892
ACTG	0.887
ATOS	0.884
EML	0.884
HEAR	0.883
EFSCP	0.88

10 最负相关
RGC	-0.897
TSP	-0.894
ZUMZ	-0.878
RMGC	-0.877
RMRM	-0.876
ORPH	-0.873
RGF	-0.872
ATAK	-0.87
IMRX	-0.869
BTTX	-0.869

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Brainstorm Cell 相关性 - 货币/商品

-0.73
( moderate negative )

-0.39
( neutral )

0.00
( neutral )

-0.20
( neutral )

-0.49
( neutral )

0.65
( moderate )

Brainstorm Cell 财务报表

Annual	2023
营收:	$0
毛利润:	$-265 000 (0.00 %)
EPS:	$-0.400

FY	2023
营收:	$0
毛利润:	$-265 000 (0.00 %)
EPS:	$-0.400

FY	2022
营收:	$0
毛利润:	$-285 000 (0.00 %)
EPS:	$-0.650

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Brainstorm Cell

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.